- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented…
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients…
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at…
SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance…
New data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes-highlighting its potential…
Company advances development of first-in-class solid tumor immunotherapy platformLOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Tidewave Bio, a biotechnology…
The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD…
Groundbreaking study in Communications Medicine highlights AI's role in transforming immunotherapy decisions and precision oncology IRVING, Texas, Aug. 6, 2025…